Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 (A) Immunochemistry for matrix metalloproteinase (MMP)-9 and sirius red staining (x630; box, x400) for collagen content (x100) in asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques. Similar regions of plaque are shown. These results are typical of asymptomatic, placebo-treated and rosiglitazone-treated symptomatic plaques. (B) Enzyme-linked immunosorbent assay for MMP-9 and sirius red staining for collagen content in asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques. (The central line represents the median, the boxes span from the 25th to 75th percentiles, and the error bars extend from the 10th to 90th percentiles.) *p < 0.05 compared with placebo group.  p < 0.05 compared with rosiglitazone group.
|
